COVID-19 vaccine

New CDC Respiratory Guidance Ignores Kidney Patient Concerns

Retrieved on: 
Thursday, March 7, 2024

WASHINGTON, March 7, 2024 /PRNewswire/ -- Today, the American Association of Kidney Patients (AAKP), the largest and oldest independent kidney patient organization in the nation, issued an Official Statement (appears below) in response to the Center for Disease Prevention and Control's (CDC) new Respiratory Virus Guidance, publicly announced on March 1, 2024. The CDC announcement occurred on the first day of National Kidney Month. March traditionally unites kidney stakeholders and people of goodwill in efforts to raise awareness of kidney diseases, address ongoing unmet patient needs, and advocate for removal of federal regulatory and payment barriers that impede access to, and development of, new kidney diagnostics, drugs, and devices.

Key Points: 
  • Mortality rates among kidney patients occurred at historic levels at the start of the COVID pandemic, devastated the kidney patient community and families, and this community's ongoing risks remain a strategic concern among patient advocates and allied kidney professionals.
  • AAKP also raised kidney patient health and safety concerns to CDC officials in stakeholder briefings prior to the March 1, 2024, CDC Respiratory Virus Guidance announcement.
  • The American Association of Kidney Patients (AAKP), the nation's largest and oldest independent kidney patient organization in the nation, is deeply concerned about the Center for Disease Prevention Control's (CDC) Respiratory Virus Guidelines, including for COVID, announced on March 1, 2024.
  • https://www.cdc.gov/mmwr/volumes/73/wr/mm7308a5.htm
    Since 1969, The American Association of Kidney Patients has been a patient-led organization driving policy discussions on kidney patient care choice and medical innovation.

Cayman Chemical Introduces LipidLaunch™, Expands Portfolio of Lipid Nanoparticle Research Tools to Support Advances in RNA Therapies

Retrieved on: 
Tuesday, February 20, 2024

ANN ARBOR, Mich., Feb. 20, 2024 /PRNewswire-PRWeb/ -- Cayman Chemical, a leading supplier of research tools for lipid nanoparticles (LNPs), announced today the introduction of LipidLaunch™ research-ready LNPs and reagent kits. The LipidLaunch™ product line is the latest addition to the company's portfolio of LNP research tools and reflects the company's legacy of providing high-quality lipids for academic, pharma, and biotech researchers worldwide.

Key Points: 
  • Cayman Chemical introduces the latest addition to the company's portfolio of lipid nanoparticle (LNP) research tools for academic, pharma, and biotech researchers worldwide.
  • ANN ARBOR, Mich., Feb. 20, 2024 /PRNewswire-PRWeb/ -- Cayman Chemical, a leading supplier of research tools for lipid nanoparticles (LNPs), announced today the introduction of LipidLaunch™ research-ready LNPs and reagent kits.
  • The LipidLaunch™ product line is the latest addition to the company's portfolio of LNP research tools and reflects the company's legacy of providing high-quality lipids for academic, pharma, and biotech researchers worldwide.
  • Cayman's LipidLaunch™ products support LNP research and development from discovery to bioanalysis with a range of purpose-built solutions.

NCLA Asks Supreme Court to Uphold Injunction Against Government Social Media Censorship

Retrieved on: 
Tuesday, February 6, 2024

The injunction would bar officials from the White House, CDC, FBI, Cybersecurity and Infrastructure Security Agency (CISA), and Surgeon General’s office from coercing or significantly encouraging social media platforms to censor constitutionally protected speech.

Key Points: 
  • The injunction would bar officials from the White House, CDC, FBI, Cybersecurity and Infrastructure Security Agency (CISA), and Surgeon General’s office from coercing or significantly encouraging social media platforms to censor constitutionally protected speech.
  • In September, a Fifth Circuit panel upheld the key components of U.S. District Judge Terry Doughty’s July 4 preliminary injunction order, prohibiting named federal officials from coercing or significantly encouraging social media companies to suppress legal speech.
  • Though the U.S. Supreme Court has temporarily stayed the Fifth Circuit’s injunction, NCLA believes the Justices are ultimately unlikely to permit the egregious First Amendment abridgements this case has exposed.
  • In fact, much of the speech the government suppressed in this case—about Covid-19 and Hunter Biden’s laptop—was truthful.”
    — Mark Chenoweth, President and Chief Legal Officer, NCLA

Viral Sensitizers Market Research Report 2023: Viral Vaccines, Oncolytic Viral Therapies and Viral Vectors - Global Industry Trends and Forecasts, 2020-2022 and 2023-2035 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 6, 2024

The "Viral Sensitizers Market: Distribution by Application Area (Viral Vaccines, Oncolytic Viral Therapies and Viral Vectors) and Key Geographical Regions (North America, Europe and Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2023-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Viral Sensitizers Market: Distribution by Application Area (Viral Vaccines, Oncolytic Viral Therapies and Viral Vectors) and Key Geographical Regions (North America, Europe and Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2023-2035" report has been added to ResearchAndMarkets.com's offering.
  • The market research report highlights the efforts of several stakeholders engaged in this rapidly evolving segment of the viral manufacturing industry.
  • Key takeaways of the viral sensitizers market report are briefly discussed below.
  • We have extensively studied the historical market data within this industry, in order to develop a deeper understanding of the evolutionary market trends.

Cencora Reports Fiscal 2024 First Quarter Results

Retrieved on: 
Wednesday, January 31, 2024

Operating income as a percentage of revenue was 1.14 percent in the first quarter of fiscal 2024, an increase of 13 basis points when compared to the prior year quarter.

Key Points: 
  • Operating income as a percentage of revenue was 1.14 percent in the first quarter of fiscal 2024, an increase of 13 basis points when compared to the prior year quarter.
  • Diluted Earnings Per Share: Diluted earnings per share was $2.98 in the first quarter of fiscal 2024, a 27.9 percent increase compared to $2.33 in the previous fiscal year’s first quarter.
  • Diluted Shares Outstanding: Diluted weighted average shares outstanding for the first quarter of fiscal 2024 were 201.8 million, a decrease of 2.2 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.
  • Adjusted Diluted Earnings Per Share: Adjusted diluted earnings per share was $3.28 in the first quarter of fiscal 2024, a 21.0% increase compared to $2.71 in the previous fiscal year’s first quarter.

Henry Schein to Webcast Fourth Quarter and Full-Year 2023 Conference Call and Introduce Its Full-Year 2024 Guidance on Tuesday, February 27, 2024 at 10:00 A.M. ET

Retrieved on: 
Tuesday, January 23, 2024

The Company will also introduce its earnings expectations for the full-year 2024.

Key Points: 
  • The Company will also introduce its earnings expectations for the full-year 2024.
  • Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer.
  • A replay will be available on the Henry Schein website following the presentation.
  • We undertake no duty and have no obligation to update forward-looking statements except as required by law.

Global Medicine Spending to Reach $2.3 Trillion by 2028 as More Patients Get Access to Better Therapies, Says IQVIA Institute Report

Retrieved on: 
Wednesday, January 17, 2024

Overall, global use and spending on medicines is exceeding pre-pandemic growth rates and is expected to continue significantly above these trends through 2028.

Key Points: 
  • Overall, global use and spending on medicines is exceeding pre-pandemic growth rates and is expected to continue significantly above these trends through 2028.
  • Spending in key therapy areas: Oncology and obesity lead growth while immunology spending has slowed due to biosimilar availability and uptake.
  • The spending on global biotech is expected to exceed $892 billion by 2028, with growth slowing to 9.5-12.5% from biosimilar savings.
  • Specialty medicines will represent about 43% of global spending in 2028 and 55% of total spending in leading developed markets.

Special Issue of American Journal of Public Health Illuminates Lessons Learned from COVID-19 Pandemic

Retrieved on: 
Monday, January 15, 2024

Vaccines against the SARS-CoV-2 virus have been crucial to preventing infection, reducing hospitalizations and deaths and limiting the public health impact during the COVID-19 pandemic.

Key Points: 
  • Vaccines against the SARS-CoV-2 virus have been crucial to preventing infection, reducing hospitalizations and deaths and limiting the public health impact during the COVID-19 pandemic.
  • By 2023, CEAL expanded to support community-engaged research in additional areas, including maternal health, climate health, health knowledge and primary care.
  • CEAL's mission is to promote health equity, improve health outcomes and strengthen community partnerships to address health disparities.
  • The American Public Health Association champions the health of all people and all communities.

Why have authoritarianism and libertarianism merged? A political psychologist on 'the vulnerability of the modern self'

Retrieved on: 
Tuesday, January 2, 2024

To be libertarian is to see the freedom of the individual as the supreme principle of politics.

Key Points: 
  • To be libertarian is to see the freedom of the individual as the supreme principle of politics.
  • It is core to the economics and politics of neo-liberalism, as well as to some bohemian counter-cultures.
  • Consider Donald Trump, whose re-election in 2024 would be seen by many as adding to the international rise of authoritarianism.
  • Alongside them were the Proud Boys, whose misty libertarianism is paired with a proto-authoritarian commitment to politics as violence.

New age meets anti-vax

  • But they were also facilitated by libertarian ideologies which rationalise suspicion of and antipathy towards authority of all sorts – and support refusals to comply with public health measures.
  • One might have thought that Totnes and some other towns like it would be the last places we’d find sympathy for authoritarian politics.
  • And of that group, 60% believed the use of violence in the name of such a movement would be justified.

Two responses to the same anxiety

  • As Erich Fromm and others have shown, our ideological affinities are linked to unconscious structures of feeling.
  • At this level, authoritarianism and libertarianism are the interchangeable products of the same underlying psychological difficulty: the vulnerability of the modern self.
  • Authoritarian political movements offer a sense of belonging to a collective, and of being protected by its strong leader.
  • This may be completely illusory, but it nonetheless provides a sense of safety in a world of threatening change and risk.


Barry Richards does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 11, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 11, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 11, Status: Authorised